229 related articles for article (PubMed ID: 28244062)
21. Multiple eruptive squamous cell carcinomas: a possible clinical sign in melanoma patients treated with vemurafenib.
Jovic A; Tiodorovic D; Popovic D; Vidovic N; Zlatanovic Z; Cekic S; Kocic H; Damiani G
Eur J Dermatol; 2021 Apr; 31(2):279-280. PubMed ID: 34001482
[No Abstract] [Full Text] [Related]
22. Interleukin-2-associated bullous drug dermatosis.
Hofmann M; Audring H; Sterry W; Trefzer U
Dermatology; 2005; 210(1):74-5. PubMed ID: 15604553
[No Abstract] [Full Text] [Related]
23. Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
Zonta E; Chiarion V; Zarian H; Peserico A; Alaibac M
Melanoma Res; 2012 Jun; 22(3):284-5. PubMed ID: 22543678
[No Abstract] [Full Text] [Related]
24. N-Ras mutation in vemurafenib-associated expanding melanocytic nevus.
Harada K; Kato Y; Maeda T; Yoshida M; Irisawa R; Nagao T; Tsuboi R
J Dermatol; 2017 May; 44(5):e101-e102. PubMed ID: 27790745
[No Abstract] [Full Text] [Related]
25. Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma.
Fusumae T; Kamiya K; Maekawa T; Komine M; Murata S; Inoda S; Takahashi R; Kawashima H; Ohtsuki M
J Dermatol; 2018 Jun; 45(6):e159-e160. PubMed ID: 29314171
[No Abstract] [Full Text] [Related]
26. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption.
Gupta M; Huang V; Linette G; Cornelius L
Arch Dermatol; 2012 Aug; 148(8):966-8. PubMed ID: 22911209
[No Abstract] [Full Text] [Related]
27. [Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib].
de Masson A; Bouvresse S; Clérici T; Mahé E; Saïag P
Ann Dermatol Venereol; 2011 Feb; 138(2):135-9. PubMed ID: 21333826
[TBL] [Abstract][Full Text] [Related]
28. Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma.
Ramani NS; Curry JL; Kapil J; Rapini RP; Tetzlaff MT; Prieto VG; Torres-Cabala CA
Am J Dermatopathol; 2015 Aug; 37(8):e96-9. PubMed ID: 25839886
[TBL] [Abstract][Full Text] [Related]
29. [Persistent inflammatory reaction at the injection site of Il-2 with lymphoma-like inflammatory infiltrates].
Assmann K; Nashan D; Grabbe S; Luger TA; Metze D
Hautarzt; 2002 Aug; 53(8):554-7. PubMed ID: 12221472
[TBL] [Abstract][Full Text] [Related]
30. Eccrine squamous syringometaplasia associated with vemurafenib therapy.
Story SG; Beschloss JK; Dolan CK; Thomas BC
J Am Acad Dermatol; 2012 Nov; 67(5):e208-10. PubMed ID: 23062917
[No Abstract] [Full Text] [Related]
31. Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma.
Eser Öztürk H; Süllü Y
Turk J Ophthalmol; 2020 Mar; 50(1):50-52. PubMed ID: 32167264
[TBL] [Abstract][Full Text] [Related]
32. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
[TBL] [Abstract][Full Text] [Related]
33. Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment.
Komori T; Otsuka A; Kaku Y; Honda T; Kabashima K
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):e474-e475. PubMed ID: 28426905
[No Abstract] [Full Text] [Related]
34. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib.
Kim GH; Levy A; Compoginis G
J Cutan Pathol; 2013 Jul; 40(7):667-9. PubMed ID: 23581649
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy.
Rhee do Y; Won KH; Lee YJ; Won CH; Chang SE; Lee MW
J Dermatolog Treat; 2016 Oct; 27(5):448-9. PubMed ID: 27092864
[TBL] [Abstract][Full Text] [Related]
36. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
37. Vemurafenib-induced plantar hyperkeratosis.
Bashline BR; Bedocs PM
Cutis; 2018 Sep; 102(3):E19-E21. PubMed ID: 30372722
[No Abstract] [Full Text] [Related]
38. A case of occipital neuralgia in a vemurafenib-treated melanoma patient.
Hoashi T; Matsumoto N; Serizawa N; Kataoka K; Nako T; Shirakawa N; Matano Y; Funasaka Y; Saeki H
Int J Dermatol; 2017 Jan; 56(1):e10-e11. PubMed ID: 27653311
[No Abstract] [Full Text] [Related]
39. Targeting the adnexal epithelium: an unusual case of syringometaplasia in a patient on vemurafenib.
Yu J; Ravikumar S; Plaza JA; Troy JL; Schieke SM
Am J Dermatopathol; 2015 May; 37(5):e57-60. PubMed ID: 25839889
[TBL] [Abstract][Full Text] [Related]
40. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
Arianayagam S; Ieremia E; Matin RN
Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
